Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 339-345

  Fukuma, Y ^a   Matsui, H ^a   Koike, H ^a   Sekine, Y ^a   Shechter, I ^b   Ohtake, N ^a   Nakata, S ^a   Ito, K ^a   Suzuki, K ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FDFT1; genetic polymorphism; squalene synthase

Indexed keywords

LAPAQUISTAT; MESSENGER RNA; SMALL INTERFERING RNA; SQUALENE SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ADULT; AGED; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME INHIBITION; EXON; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CELL LINE, TUMOR; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; GENETIC ASSOCIATION STUDIES; GENETIC LINKAGE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84869220602     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.14     Document Type: Review

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. Cancer Epidemiol Biomarkers Prev 2008; 17: 930-937. (Pubitemid 351536425)
4. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols. IV-IX. Jpn J Clin Oncol 2009; 39: 468-469.
5. Ohtake N, Hatori M, Yamanaka H, Nakata S, Sada M, Tsuji T. Familial prostate cancer in Japan. Int J Urol 1998; 5: 138-145. (Pubitemid 28197308)
6. Matsui H, Suzuki K, Ohtake N, Nakata S, Takeuchi T, Yamanaka H et al. Genomewide linkage analysis of familial prostate cancer in the Japanese population. J Hum Genet 2004; 49: 9-15. (Pubitemid 38186119)
7. Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 1999; 12: 4013-4020. (Pubitemid 30013778)
8. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 2: 181-184.
9. Datta MW, Hernandez AM, Schlicht MJ, Kahler AJ, DeGueme AM, Dhir R et al. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol Cancer 2006; 5: 9.
10. Sekine Y, Koike H, Nakano T, Nakajima K, Takahashi S, Suzuki K. Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor. Cancer Epidemiol 2009; 33: 16-23.
11. Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K et al. High-density lipoprotein induces proliferation and migration of human prostate androgenindependent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res 2010; 8: 1284-1294.
12. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 2008; 372: 356-361.
13. Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J et al. Mevalonateregulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997; 7: 625-633. (Pubitemid 27308491)
14. Miziorko HM. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch Biochem Biophys 2011; 502: 131-143.
15. Shechter I, Klinger E, Rucker ML, Engstrom RG, Spirito JA, Islam MA et al. Solubilization, purification, and characterization of a truncated form of rat hepatic squalene synthetase. J Biol Chem 1992; 267: 8628-8635.
16. Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I et al. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem 2007; 282: 18777-18785. (Pubitemid 47100167)
17. Okamura K, Koike H, Matsui H, Suzuki K. Gene expression profiles of prostate cancer cell lines, LNCaP, PC-3 and DU-145, assessed by cDNA microarray. Kitakanto Med J 2008; 58: 363-369.
18. Hamano T, Matsui H, Sekine Y, Ohtake N, Nakata S, Suzuki K. Association of SNP rs1447295 and microsatellite marker DG8S737 with familial prostate cancer and high grade disease. J Urol 2010; 184: 738-742.
19. Guan G, Jiang G, Koch RL, Shechter I. Molecular cloning and functional analysis of the promoter of the human squalene synthase gene. J Biol Chem 1995; 270: 21958-21965.
20. Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H et al. Lipidlowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 2003; 139: 911-918. (Pubitemid 36877390)
21. Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K. Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. J Urol 2011; 185: 1497-1503.
22. Nomura M, Ito K, Miyakubo M, Sekine Y, Tamura Y, Shimizu N et al. Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy-and prostate volume-adjusted biopsy scheme. Prostate Cancer Prostatic Dis, e-pub ahead of print 6 December 2011.
23. Guan G, Dai PH, Osborne TF, Kim JB, Shechter I. Multiple sequence elements are involved in the transcriptional regulation of the human squalene synthase gene. J Biol Chem 1997; 272: 10295-10302. (Pubitemid 27171712)
24. Guan G, Dai P, Shechter I. Differential transcriptional regulation of the human squalene synthase gene by sterol regulatory element-binding proteins (SREBP) 1a and 2 and involvement of 50 DNA sequence elements in the regulation. J Biol Chem 1998; 273: 12526-12535. (Pubitemid 28240627)
25. Do R, Pare G, Montpetit A, Hudson TJ, Gaudet D, Engert JC. K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population. Hum Mutat 2008; 29: 689-694. (Pubitemid 351614593)
26. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S et al. Genomewide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567-1576.
27. Ballestri S, Day CP, Daly AK. Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. Gastroenterology 2011; 140: 1694-1695.
28. Brown MS, Goldstein JL, Siperstein MD. Regulation of cholesterol synthesis in normal and malignant tissue. Fed Proc 1973; 32: 2168-2173.
29. Tansey TR, Shechter I. Structure and regulation of mammalian squalene synthase. Biochim Biophys Acta 2000; 1529: 49-62.
30. Swyer GIM. The cholesterol content of normal and enlarged prostates. Cancer Res 1942; 2: 372-375.
31. Acevedo HF, Campbell EA, Saier EL, Frich Jr JC, Merkow LP, Hayeslip DW et al. Urinary cholesterol V. Its excretion in men with testicular and prostatic neoplasms. Cancer 1973; 32: 196-205.
32. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 2007; 67: 1061-1069. (Pubitemid 46991915)
33. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-968. (Pubitemid 40489400)
34. Epstein JI. An update of the Gleason grading system. J Urol 2010; 183: 433-440.
35. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 1998; 95: 12410-12415. (Pubitemid 28483779)
36. Swinnen JV, Ulrix W, Heyns W, Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA 1997; 94: 12975-12980. (Pubitemid 27518461)
37. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001; 15: 1817-1828. (Pubitemid 32939311)
38. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W et al. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 273-279. (Pubitemid 40128248)
39. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009; 9: 626-638.
40. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 2011; 67: 729-739.
41. Koul HK, Koul S, Meacham RB. New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer Prostatic Dis, e-pub ahead of print 30 August 2011.
42. Sun S, McKenna CE. Farnesyl pyrophosphate synthase modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011; 21: 1433-1451.
43. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825. (Pubitemid 46017933)
44. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185: 1268-1273.
45. Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 713-718.
46. Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 2011; 18: 876-881.